Alpha v integrin inhibitors and cancer therapy

Area of Science:

• Integrin biology
• Pharmacology
• Oncology

Background:

• Alpha v integrins are cell surface receptors involved in tumor progression.
• Two alpha v integrin antagonists, Vitaxin and cilengitide, are in Phase II clinical trials for oncology.
• Peptide-derived agents face challenges with pharmacokinetics and oral bioavailability.

Purpose of the Study:

• To review the development of alpha v integrin antagonists for cancer treatment.
• To evaluate the potential of small synthetic heterocyclic inhibitors as successors to peptide-derived agents.
• To discuss the feasibility of heterocyclic inhibitors in cancer therapy, imaging, and drug delivery.

Main Methods:

• Literature review of gene disruption experiments and clinical trial data.
• Analysis of lead compounds and their mechanisms of action.
• Comparison of peptide-derived agents with synthetic heterocyclic inhibitors.

Main Results:

• Alpha v integrin targeting strategies yield varied outcomes in preventing tumor progression.
• Peptide-based alpha v integrin antagonists are progressing in clinical trials.
• The potential of synthetic heterocyclic inhibitors with improved pharmacokinetic profiles is under investigation.

Conclusions:

• Synthetic heterocyclic inhibitors may offer advantages over peptide-derived agents for alpha v integrin antagonism.
• Further research is needed to determine the efficacy and safety of heterocyclic inhibitors in oncology.
• The development of novel alpha v integrin antagonists holds promise for cancer treatment, imaging, and drug targeting.